Is CRBP or QUCY more profitable?

Mainz Biomed's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Mainz Biomed N/A N/A N/A

Does the media favor CRBP or QUCY?

In the previous week, Corbus Pharmaceuticals and Corbus Pharmaceuticals both had 5 articles in the media. Corbus Pharmaceuticals' average media sentiment score of 1.05 beat Mainz Biomed's score of 0.48 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend QUCY or HURA?

TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 345.54%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is QUCY or HURA more profitable?

Mainz Biomed's return on equity of 0.00% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A TuHURA Biosciences N/A -156.12% -105.38%

Does the media favor QUCY or HURA?

In the previous week, Mainz Biomed had 3 more articles in the media than TuHURA Biosciences. MarketBeat recorded 5 mentions for Mainz Biomed and 2 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.93 beat Mainz Biomed's score of 0.48 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TuHURA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SPRB or QUCY?

Spruce Biosciences currently has a consensus price target of $169.67, suggesting a potential upside of 246.05%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Spruce Biosciences is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SPRB or QUCY more profitable?

Mainz Biomed's return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% Mainz Biomed N/A N/A N/A

Does the media favor SPRB or QUCY?

In the previous week, Spruce Biosciences had 3 more articles in the media than Mainz Biomed. MarketBeat recorded 8 mentions for Spruce Biosciences and 5 mentions for Mainz Biomed. Spruce Biosciences' average media sentiment score of 1.12 beat Mainz Biomed's score of 0.48 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GNLX or QUCY?

Genelux currently has a consensus target price of $18.00, suggesting a potential upside of 504.03%. Given Genelux's stronger consensus rating and higher possible upside, research analysts clearly believe Genelux is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, GNLX or QUCY?

Mainz Biomed has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 13,362.32 -$32.15M -$0.85 N/A Mainz Biomed $540K 55.38 -$16.21M -$47.60 N/A

Is GNLX or QUCY more profitable?

Mainz Biomed's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Mainz Biomed N/A N/A N/A

Does the media favor GNLX or QUCY?

In the previous week, Mainz Biomed had 2 more articles in the media than Genelux. MarketBeat recorded 5 mentions for Mainz Biomed and 3 mentions for Genelux. Mainz Biomed's average media sentiment score of 0.48 beat Genelux's score of 0.43 indicating that Mainz Biomed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CRDL or QUCY?

Cardiol Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 687.04%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is CRDL or QUCY more profitable?

Mainz Biomed's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Mainz Biomed N/A N/A N/A

Mainz Biomed (QUCY) Competitors

$2.04 -0.06 (-2.86%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$2.04 +0.00 (+0.25%)

As of 04:53 AM Eastern

Compare

QUCY vs. CRBP, HURA, SPRB, GNLX, and CRDL

Should you buy Mainz Biomed stock or one of its competitors? MarketBeat compares Mainz Biomed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mainz Biomed include Corbus Pharmaceuticals (CRBP), TuHURA Biosciences (HURA), Spruce Biosciences (SPRB), Genelux (GNLX), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry.

How does Mainz Biomed compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Corbus Pharmaceuticals presently has a consensus target price of $42.00, suggesting a potential upside of 445.45%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Corbus Pharmaceuticals is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Mainz Biomed has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Mainz Biomed	$540K	55.38	-$16.21M	-$47.60	N/A

Corbus Pharmaceuticals has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market.

In the previous week, Corbus Pharmaceuticals and Corbus Pharmaceuticals both had 5 articles in the media. Corbus Pharmaceuticals' average media sentiment score of 1.05 beat Mainz Biomed's score of 0.48 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mainz Biomed's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Mainz Biomed	N/A	N/A	N/A

Summary

Corbus Pharmaceuticals beats Mainz Biomed on 9 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to TuHURA Biosciences?

Mainz Biomed (NASDAQ:QUCY) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Mainz Biomed's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
TuHURA Biosciences	N/A	-156.12%	-105.38%

TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 345.54%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

0.6% of TuHURA Biosciences shares are owned by institutional investors. 3.1% of Mainz Biomed shares are owned by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Mainz Biomed has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

In the previous week, Mainz Biomed had 3 more articles in the media than TuHURA Biosciences. MarketBeat recorded 5 mentions for Mainz Biomed and 2 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.93 beat Mainz Biomed's score of 0.48 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mainz Biomed has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$540K	55.38	-$16.21M	-$47.60	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Summary

Mainz Biomed beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

91.7% of Spruce Biosciences shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Comparatively, 3.1% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Spruce Biosciences currently has a consensus price target of $169.67, suggesting a potential upside of 246.05%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Spruce Biosciences is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Spruce Biosciences had 3 more articles in the media than Mainz Biomed. MarketBeat recorded 8 mentions for Spruce Biosciences and 5 mentions for Mainz Biomed. Spruce Biosciences' average media sentiment score of 1.12 beat Mainz Biomed's score of 0.48 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mainz Biomed has lower revenue, but higher earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	27.46	-$38.97M	-$36.60	N/A
Mainz Biomed	$540K	55.38	-$16.21M	-$47.60	N/A

Spruce Biosciences has a beta of 3.11, suggesting that its stock price is 211% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Mainz Biomed	N/A	N/A	N/A

Summary

Spruce Biosciences beats Mainz Biomed on 10 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to Genelux?

Genelux (NASDAQ:GNLX) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Mainz Biomed has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,362.32	-$32.15M	-$0.85	N/A
Mainz Biomed	$540K	55.38	-$16.21M	-$47.60	N/A

Mainz Biomed's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Mainz Biomed	N/A	N/A	N/A

Genelux currently has a consensus target price of $18.00, suggesting a potential upside of 504.03%. Given Genelux's stronger consensus rating and higher possible upside, research analysts clearly believe Genelux is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Genelux has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.22, meaning that its stock price is 122% more volatile than the broader market.

37.3% of Genelux shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 3.1% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Mainz Biomed had 2 more articles in the media than Genelux. MarketBeat recorded 5 mentions for Mainz Biomed and 3 mentions for Genelux. Mainz Biomed's average media sentiment score of 0.48 beat Genelux's score of 0.43 indicating that Mainz Biomed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mainz Biomed beats Genelux on 8 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Mainz Biomed had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 5 mentions for Mainz Biomed and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.89 beat Mainz Biomed's score of 0.48 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Very Positive
Mainz Biomed	Neutral

Mainz Biomed's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Mainz Biomed	N/A	N/A	N/A

Cardiol Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 687.04%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cardiol Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 3.1% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mainz Biomed has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Mainz Biomed	$540K	55.38	-$16.21M	-$47.60	N/A

Summary

Cardiol Therapeutics and Mainz Biomed tied by winning 7 of the 14 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QUCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QUCY vs. The Competition

Export

Metric	Mainz Biomed	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$30.79M	$958.36M	$4.87B	$12.06B
Dividend Yield	N/A	4.84%	9.42%	5.55%
P/E Ratio	-0.04	1.46	21.74	23.76
Price / Sales	55.38	127.56	173.03	105.22
Price / Cash	N/A	20.06	43.40	56.09
Price / Book	29.14	7.90	28.96	6.72
Net Income	-$16.21M	-$4.82M	$118.48M	$337.35M
7 Day Performance	-17.07%	-1.57%	-2.61%	-1.21%
1 Month Performance	461.36%	3.80%	-0.09%	1.41%
1 Year Performance	N/A	96.26%	12.12%	23.64%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QUCY Mainz Biomed	0.872 of 5 stars	$2.04 -2.9%	N/A	N/A	$30.79M	$540K	N/A	30	Short Interest Decrease Gap Down
CRBP Corbus Pharmaceuticals	4.3642 of 5 stars	$7.91 +3.5%	$42.00 +431.0%	-16.4%	$146.57M	N/A	N/A	40	Positive News High Trading Volume
HURA TuHURA Biosciences	2.1086 of 5 stars	$2.26 -3.8%	$9.00 +298.2%	-29.9%	$143.92M	N/A	N/A	N/A
SPRB Spruce Biosciences	3.0149 of 5 stars	$51.38 +4.5%	$186.60 +263.2%	+989.6%	$141.30M	$4.91M	N/A	20	Positive News Analyst Forecast Gap Up
GNLX Genelux	2.0268 of 5 stars	$3.05 -0.7%	$18.00 +490.2%	+10.0%	$136.76M	$10K	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QUCY) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (QUCY) Competitors

QUCY vs. CRBP, HURA, SPRB, GNLX, and CRDL

How does Mainz Biomed compare to Corbus Pharmaceuticals?

Summary

How does Mainz Biomed compare to TuHURA Biosciences?

Summary

How does Mainz Biomed compare to Spruce Biosciences?

Summary

How does Mainz Biomed compare to Genelux?

Summary

How does Mainz Biomed compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QUCY vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (QUCY) Competitors

QUCY vs. CRBP, HURA, SPRB, GNLX, and CRDL

How does Mainz Biomed compare to Corbus Pharmaceuticals?

Do analysts prefer CRBP or QUCY?

Do insiders & institutionals have more ownership in CRBP or QUCY?

Which has higher valuation & earnings, CRBP or QUCY?

Which has more volatility & risk, CRBP or QUCY?

Does the media favor CRBP or QUCY?

Is CRBP or QUCY more profitable?

Summary

How does Mainz Biomed compare to TuHURA Biosciences?

Is QUCY or HURA more profitable?

Do analysts recommend QUCY or HURA?

Do insiders and institutionals have more ownership in QUCY or HURA?

Which has more volatility & risk, QUCY or HURA?

Does the media favor QUCY or HURA?

Which has higher earnings & valuation, QUCY or HURA?

Summary

How does Mainz Biomed compare to Spruce Biosciences?

Do institutionals & insiders have more ownership in SPRB or QUCY?

Do analysts recommend SPRB or QUCY?

Does the media favor SPRB or QUCY?

Which has preferable valuation & earnings, SPRB or QUCY?

Which has more risk and volatility, SPRB or QUCY?

Is SPRB or QUCY more profitable?

Summary

How does Mainz Biomed compare to Genelux?

Which has stronger earnings and valuation, GNLX or QUCY?

Is GNLX or QUCY more profitable?

Do analysts recommend GNLX or QUCY?

Which has more risk & volatility, GNLX or QUCY?

Do institutionals and insiders have more ownership in GNLX or QUCY?

Does the media favor GNLX or QUCY?

Summary

How does Mainz Biomed compare to Cardiol Therapeutics?

Does the media favor CRDL or QUCY?

Is CRDL or QUCY more profitable?

Do analysts recommend CRDL or QUCY?

Which has more volatility & risk, CRDL or QUCY?

Do insiders and institutionals have more ownership in CRDL or QUCY?

Which has better valuation and earnings, CRDL or QUCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QUCY vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools